{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:52:14Z","timestamp":1781578334979,"version":"3.54.5"},"reference-count":56,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>No prior meta-analysis has systematically assessed efficacy and safety of C-type natriuretic peptide (CNP) analogs within the context of evolving understanding of FGFR3 biology and achondroplasia natural history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of CNP analogs in children with achondroplasia and contextualize clinical outcomes and natural history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review of randomized control trials and real-world studies evaluating the safety and efficacy of CNP analogs (vosoritide and navepegritide) in children aged &amp;lt;18 years with genetically confirmed achondroplasia was performed. Coprimary outcomes of interest were adverse events (AEs) and changes from baseline in annualized growth velocity (AGV) at the end of the trials. Secondary outcomes included changes from baseline in height Z-score, standing height, and upper-to-lower body segment (ULS) ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven studies (N = 542) were included, of which 4 RCTs (n = 326) with low overall risk of bias were meta-analyzed. Overall and serious AE rates were comparable between CNP analogs and placebo, except for higher relative risks of injection site reactions (1.65), urticaria (4.04), and swelling (3.57). C-type natriuretic peptide analogs significantly increased mean differences in AGV (1.36\u2005cm\/year; 95% CI: 1.05-1.68; P &amp;lt; .00001) and standing height (1.24\u2005cm; 95% CI: 0.47-2.01; P = .002), without short-term effect on ULS ratio. Real-world studies demonstrated sustained growth benefits with infrequent serious AEs or treatment discontinuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>C-type natriuretic peptide analogs provide slight but statistically meaningful improvements in linear growth in children with achondroplasia with acceptable short-term safety profile. Long-term studies are needed to define optimal timing of therapy on adult height, functional outcomes, and achondroplasia-related complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag121","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:22:08Z","timestamp":1779794528000},"source":"Crossref","is-referenced-by-count":0,"title":["Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"Abul Bashar Mohammad","family":"Kamrul-Hasan","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Mymensingh Medical College , Mymensingh 2200 ,","place":["Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-0734","authenticated-orcid":false,"given":"Suma","family":"Uday","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Diabetes & Metabolic Bone Disease, Narayana Health City , Bengaluru 560099 ,","place":["India"]},{"name":"Department of Metabolism System Science, University of Birmingham , Birmingham B15 2TT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-5554","authenticated-orcid":false,"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research , Mysuru, Karnataka 570015 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CEDAR Superspeciality Healthcare , New Delhi 110075 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-9371","authenticated-orcid":false,"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Indraprastha Apollo Hospitals , New Delhi 110076 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-5255","authenticated-orcid":false,"given":"Joseph M","family":"Pappachan","sequence":"additional","affiliation":[{"name":"Faculty of Science, Manchester Metropolitan University , Manchester, Greater Manchester M15 6BH ,","place":["UK"]},{"name":"Department of Endocrinology, Countess of Chester Hospital NHS Foundation Trust , Chester, Cheshire CH2 1UL ,","place":["UK"]},{"name":"Department of Endocrinology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal 576104 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-6624","authenticated-orcid":false,"given":"Ambika P","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Diabetes, University of Alabama at Birmingham , Birmingham, AL 35243 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026061522013831400_bvag121-B1","doi-asserted-by":"crossref","first-page":"117275","DOI":"10.1016\/j.bmc.2023.117275","article-title":"Current and emerging therapies for achondroplasia: the Dawn of precision medicine","volume":"87","author":"Dardenne","year":"2023","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"2026061522013831400_bvag121-B2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/dvdy.24479","article-title":"Achondroplasia: development, pathogenesis, and therapy","volume":"246","author":"Ornitz","year":"2017","journal-title":"Dev Dyn"},{"issue":"10","key":"2026061522013831400_bvag121-B3","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","article-title":"Birth prevalence of achondroplasia: a systematic literature review and meta-analysis","volume":"182","author":"Foreman","year":"2020","journal-title":"Am J Med Genet A"},{"issue":"6494","key":"2026061522013831400_bvag121-B4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/371252a0","article-title":"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia","volume":"371","author":"Rousseau","year":"1994","journal-title":"Nature"},{"issue":"2","key":"2026061522013831400_bvag121-B5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"Shiang","year":"1994","journal-title":"Cell"},{"issue":"4","key":"2026061522013831400_bvag121-B6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.joca.2021.11.017","article-title":"Expanding horizons of achondroplasia treatment: current options and future developments","volume":"30","author":"Fafilek","year":"2022","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"2026061522013831400_bvag121-B7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1101\/gad.1179104","article-title":"Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype","volume":"18","author":"Murakami","year":"2004","journal-title":"Genes Dev"},{"issue":"14","key":"2026061522013831400_bvag121-B8","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.266551.115","article-title":"Fibroblast growth factor signaling in skeletal development and disease","volume":"29","author":"Ornitz","year":"2015","journal-title":"Genes Dev"},{"issue":"9","key":"2026061522013831400_bvag121-B9","doi-asserted-by":"crossref","first-page":"e147832","DOI":"10.1172\/jci.insight.147832","article-title":"Prevention of guanylyl cyclase-B dephosphorylation rescues achondroplastic dwarfism","volume":"6","author":"Wagner","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"2026061522013831400_bvag121-B10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/hmg\/ddn339","article-title":"FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway","volume":"18","author":"Matsushita","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026061522013831400_bvag121-B11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s13023-021-02141-4","article-title":"Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study-a multi-center retrospective cohort study of achondroplasia in the US","volume":"16","author":"Hoover-Fong","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2026061522013831400_bvag121-B12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s41436-021-01165-2","article-title":"Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States","volume":"23","author":"Hoover-Fong","year":"2021","journal-title":"Genet Med"},{"issue":"11","key":"2026061522013831400_bvag121-B13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/ajmg.a.61825","article-title":"Natural history of achondroplasia: a retrospective review of longitudinal clinical data","volume":"182","author":"Okenfuss","year":"2020","journal-title":"Am J Med Genet A"},{"issue":"2","key":"2026061522013831400_bvag121-B14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3171\/2020.12.PEDS20715","article-title":"Achondroplasia Natural History Study (CLARITY): 60-year experience in cervicomedullary decompression in achondroplasia from four skeletal dysplasia centers","volume":"28","author":"Legare","year":"2021","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"2026061522013831400_bvag121-B15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-023-02738-x","article-title":"Achondroplasia natural history study (CLARITY): 60-year experience in orthopedic surgery from four skeletal dysplasia centers","volume":"18","author":"Nahm","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2026061522013831400_bvag121-B16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","article-title":"International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia","volume":"18","author":"Savarirayan","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2026061522013831400_bvag121-B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajmg.a.62018","article-title":"Quality of life in adults with achondroplasia in the United States","volume":"185","author":"Yonko","year":"2021","journal-title":"Am J Med Genet A"},{"issue":"6","key":"2026061522013831400_bvag121-B18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"7","key":"2026061522013831400_bvag121-B19","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/en.2008-1676","article-title":"Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias","volume":"150","author":"Yasoda","year":"2009","journal-title":"Endocrinology"},{"issue":"6","key":"2026061522013831400_bvag121-B20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bone.2005.03.006","article-title":"Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells","volume":"36","author":"Ozasa","year":"2005","journal-title":"Bone"},{"issue":"1","key":"2026061522013831400_bvag121-B21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"30","key":"2026061522013831400_bvag121-B22","doi-asserted-by":"crossref","first-page":"e2201067119","DOI":"10.1073\/pnas.2201067119","article-title":"A long-acting C-natriuretic peptide for achondroplasia","volume":"119","author":"Schneider","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026061522013831400_bvag121-B23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2026061522013831400_bvag121-B24","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1111\/bcp.15369","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP","volume":"88","author":"Breinholt","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2026061522013831400_bvag121-B25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajmg.a.61974","article-title":"Clinical charts for surveillance of growth and body proportion development in achondroplasia and examples of their use","volume":"185","author":"Neumeyer","year":"2021","journal-title":"Am J Med Genet A"},{"issue":"10252","key":"2026061522013831400_bvag121-B26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"2026061522013831400_bvag121-B27","doi-asserted-by":"crossref","first-page":"102258","DOI":"10.1016\/j.eclinm.2023.102258","article-title":"Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"65","author":"Savarirayan","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2026061522013831400_bvag121-B28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"2026061522013831400_bvag121-B29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamapediatrics.2025.4771","article-title":"Once-weekly navepegritide in children with achondroplasia: the APPROACH randomized clinical trial","volume":"180","author":"Savarirayan","year":"2026","journal-title":"JAMA Pediatr"},{"key":"2026061522013831400_bvag121-B30","author":"Higgins"},{"key":"2026061522013831400_bvag121-B31","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2026061522013831400_bvag121-B32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"2026061522013831400_bvag121-B33","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023)","author":"Higgins","year":"2023"},{"key":"2026061522013831400_bvag121-B34","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5","author":"Sterne","year":"2024"},{"issue":"4","key":"2026061522013831400_bvag121-B35","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1111\/cob.70008","article-title":"Metabolic outcomes of bariatric surgery versus lifestyle intervention in adolescents with severe obesity: a systematic review and meta-analysis","volume":"15","author":"Kamrul-Hasan","year":"2025","journal-title":"Clin Obes"},{"key":"2026061522013831400_bvag121-B36"},{"issue":"7414","key":"2026061522013831400_bvag121-B37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2026061522013831400_bvag121-B38","first-page":"608","article-title":"Real-world safety and effectiveness of vosoritide in children with achondroplasia: French early access program","author":"Cormier-Daire","year":"2026","journal-title":"Horm Res Paediatr"},{"key":"2026061522013831400_bvag121-B39","doi-asserted-by":"crossref","first-page":"102591","DOI":"10.1016\/j.eclinm.2024.102591","article-title":"Vosoritide treatment for children with hypochondroplasia: a phase 2 trial","volume":"71","author":"Dauber","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2026061522013831400_bvag121-B40","doi-asserted-by":"crossref","first-page":"bvaf041","DOI":"10.1210\/jendso\/bvaf041","article-title":"Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study","volume":"9","author":"Reincke","year":"2025","journal-title":"J Endocr Soc"},{"issue":"8","key":"2026061522013831400_bvag121-B41","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1007\/s12325-025-03223-6","article-title":"Real-world safety and effectiveness of vosoritide in achondroplasia: results from a single center in Portugal","volume":"42","author":"Rua","year":"2025","journal-title":"Adv Ther"},{"issue":"1","key":"2026061522013831400_bvag121-B42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-Type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2026061522013831400_bvag121-B43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/BPO.0000000000002980","article-title":"Changes in the alignment of the spine and lower limb in children with achondroplasia treated with vosoritide: a single-center, 1-year follow-up prospective study","volume":"45","author":"Sawamura","year":"2025","journal-title":"J Pediatr Orthop"},{"key":"2026061522013831400_bvag121-B44","doi-asserted-by":"crossref","first-page":"117722","DOI":"10.1016\/j.bone.2025.117722","article-title":"Real-world safety and age-dependent effectiveness of vosoritide in achondroplasia: a single-center retrospective analysis of transition from growth hormone to vosoritide","volume":"203","author":"Shimada","year":"2026","journal-title":"Bone"},{"issue":"1","key":"2026061522013831400_bvag121-B45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s13023-025-03853-7","article-title":"Integrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences","volume":"20","author":"Allegri","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2026061522013831400_bvag121-B46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia","volume":"61","author":"Chan","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026061522013831400_bvag121-B47","doi-asserted-by":"crossref","first-page":"131\u2013","DOI":"10.1159\/000542102","article-title":"Phase 2 trial of vosoritide use in patients with hypochondroplasia: a pharmacokinetic\/pharmacodynamic analysis","volume":"99","author":"Galetaki","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2026061522013831400_bvag121-B48","doi-asserted-by":"crossref","first-page":"100223","DOI":"10.1016\/j.gimo.2023.100223","article-title":"P194: persistence of growth promoting effects in children with achondroplasia over seven years: update from phase II extension study with vosoritide","volume":"1","author":"Hoover-Fong","year":"2023","journal-title":"Genet Med Open"},{"issue":"12","key":"2026061522013831400_bvag121-B49","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet Med"},{"issue":"12","key":"2026061522013831400_bvag121-B50","doi-asserted-by":"crossref","first-page":"101274","DOI":"10.1016\/j.gim.2024.101274","article-title":"Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life","volume":"26","author":"Savarirayan","year":"2024","journal-title":"Genet Med"},{"issue":"5","key":"2026061522013831400_bvag121-B51","doi-asserted-by":"crossref","first-page":"100566","DOI":"10.1016\/j.medj.2024.11.019","article-title":"Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study","volume":"6","author":"Savarirayan","year":"2025","journal-title":"Med"},{"issue":"1","key":"2026061522013831400_bvag121-B52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jrsm.1266","article-title":"Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests","volume":"9","author":"Debray","year":"2018","journal-title":"Res Synth Methods"},{"issue":"3","key":"2026061522013831400_bvag121-B53","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.gim.2025.101670","article-title":"Real-world outcomes of vosoritide in achondroplasia: a systematic review and meta-analysis of multinational clinical evidence","volume":"28","author":"Albuquerque AL","year":"2025","journal-title":"Genet Med"},{"issue":"1","key":"2026061522013831400_bvag121-B54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/03014460.2021.1883109","article-title":"Pubertal growth in height, sitting height and leg length in achondroplasia","volume":"48","author":"Cole","year":"2021","journal-title":"Ann Hum Biol"},{"key":"2026061522013831400_bvag121-B55","doi-asserted-by":"crossref","first-page":"1759720X221084848","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026061522013831400_bvag121-B56"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/7\/bvag121\/68531334\/bvag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/7\/bvag121\/68531334\/bvag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:01:50Z","timestamp":1781575310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag121\/8708471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag121","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,3]]},"article-number":"bvag121"}}